领航医药生物科技中期报告 2022-2023

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)( 於開曼群島註冊成立並於百慕達存續之有限公司)(Stock Code 股份代號： 399 )2022/23中期報告INTERIM REPORT Contents目錄2Corporate Information公司資料4Chairman’s Statement主席報告6Management Discussion and Analysis管理層討論及分析12Other Information Provided in Accordance with the Listing Rules根據上市規則披露之其他資料18Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income簡明綜合損益及其他全面收益表21Condensed Consolidated Statement of Financial Position簡明綜合財務狀況表24Condensed Consolidated Statement of Changes in Equity簡明綜合權益變動表26Condensed Consolidated Statement of Cash Flows簡明綜合現金流量表27Notes to the Condensed Consolidated Financial Statements簡明綜合財務報表附註 Corporate Information公司資料2INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 2022/23 Interim ReportBOARD OF DIRECTORSExecutive DirectorsGao Yuan XingTang RongNon-executive DirectorsJiang Nian (Chairman)X iao YanWu YanminIndependent non-executive DirectorsChen WeijunWang RongliangChen JinzhongAudit CommitteeChen Weijun (Chairman)Wang RongliangChen JinzhongRemuneration CommitteeWang Rongliang (Chairman) Jiang NianChen JinzhongNomination CommitteeJiang Nian (Chairman) Wang RongliangChen JinzhongHONORARY CHAIRMANMao YuminCOMPANY SECRETARYPoon Hon YinREGISTERED OFFICEClarendon House2 Church StreetHamilton HM 11, Bermuda董事會執行董事高源興唐榕非執行董事蔣年（主席）肖焱鄔燕敏獨立非執行董事陳偉君王榮樑陳金中審核委員會陳偉君（主席）王榮樑陳金中薪酬委員會王榮樑（主席）蔣年陳金中提名委員會蔣年（主席）王榮樑陳金中名譽主席毛裕民公司秘書潘漢彥註冊辦事處Clarendon House2 Church StreetHamilton HM 11, Bermuda Corporate Information公司資料32022/23年中期報告 領航醫藥及生物科技有限公司PRINCIPAL PLACE OF BUSINESS IN HONG KONGUnit No. 2111, 21/F.West Tower Shun Tak Centre168–200 Connaught Road CentralSheung Wan, Hong KongPRINCIPAL SHARE REGISTRAR AND TRANSFER AGENTConyers Corporate Services (Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11, BermudaBRANCH SHARE REGISTRAR AND TRANSFER AGENT IN HONG KONGTricor Tengis Limited17/F, Far East Finance Centre16 Harcourt RoadHong KongAUDITORSElite Partners CPA Limited10/F, 8 Observatory RoadTsim Sha Tsui, KowloonHong KongPRINCIPAL BANKERBank of Communications Co., Ltd.STOCK CODE399COMPANY WEBSITEwww.ipb.asiawww.irasia.com/listco/hk/ipb香港主要營業地點 香港上環干諾道中168 –200號信德中心西座21樓2111室股份登記總處及過戶代理處 Conyers Corporate Services (Bermuda) LimitedClarendon House2 Church StreetHamilton HM 11, Bermuda香港股份登記分處及 過戶代理處卓佳登捷時有限公司香港夏愨道16號遠東金融中心17樓核數師開元信德會計師事務所有限公司香港九龍尖沙咀天文台道8號10樓主要往來銀行交通銀行股份有限公司股份代號399公司網站www.ipb.asiawww.irasia.com/listco/hk/ipb Chairman’s Statement主席報告4INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 2022/23 Interim ReportDear Shareholders,On behalf of the board (the “Board”) of directors (the “directors”) of Innovative Pharmaceutical Biotech Limited, (the “Company”, together with its subsidiaries, the “Group”), I hereby present to all shareholders of the Company (the “Shareholders”) the unaudited consolidated financial results of the Group for the six months ended 30 September 2022 (the “Financial Period”) and the six months ended 30 September 2021 (the “Previous Financial Period”).Due to the COVID-19 is still affecting the business environment, the Group only recorded revenue of approximately HK$4.1 million for the Financial Period, a decrease of approximately 37.6% in revenue from approximately HK$6.6 million as recorded in the Previous Financial Period.The Company reported a loss for the Period amounted to approximately HK$118.3 million, as compared with the profit for the Previous Financial Period amounted to approximately HK$121.11 million. It is due to the Company completed the second amendment of the convertible bond with principal amount of HK$715 million issued by the Company during the Previous Financial Period, an amount of approximately HK$250.7 million non-cash item was credited into the income statement. 各位股東：本人謹代表領航醫藥及生物科技有限公司（「本公司」，連同其附屬公司統 稱「 本 集 團 」）之 董 事（「 董 事 」）會（「 董事 會 」）向 本 公 司 所 有 股 東（「 股 東 」）提呈本集團截至二零二二年九月三十日止六個月（「本財政期間」）及截至二零二一年九月三十日止六個月（「上一財政期間」）之未經審核綜合財務業績。由於C OV I D -19仍然影響着經營環境。本集團於本財政期間之收益僅為約4,100,000港元，較上一財政期間錄得之收益約6,600,000港元減少約3 7. 6 %。本公司於期內錄得虧損約118,300,000港元，而上一個財政期間則錄得溢利約121,110,000港元。由於本公司於上一個財政期間完成本公司所發行本金額為715,000,000港元的可換股債券第二次修訂，約250,700,000港元的非現金項目已計入收益表內。 Chairman’s Statement主席報告52022/23年中期報告 領航醫藥及生物科技有限公司OUTLOOKThe Group also engages in development of a technology that would allow insulin to be administered orally. The technology is still in the research and development stage. The Group has commenced the part B, Phase III of the clinical trial in August 2020 which is typically considered as the final stage of clinical trial before commercialization. Currently, about 296 patients have participated in the clinical trial. Although the COVID-19 affected the progress of clinical trial, the Group will use its best endeavours to commercialise the product by the mid of 2024.The Company continues to actively pursue and review cooperation, joint v